Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
Japan’s Drug Pricing Organization has made a list of proposals for the FY2016 NHI price revision next April, including one to craft a special rule under the so-called “market expansion re-pricing” scheme that would slash the prices of products hauling…
To read the full story
Related Article
- Chuikyo Payer Reps Wary of Revising Foreign Price Adjustment Rule for Govt-Requested Drugs
October 15, 2015
- Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
- FY2016 Drug Pricing Reform
August 18, 2015
- Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015
- Chuikyo Subcommittee OKs Plan to Draft GL for Analyzing Cost-Effectiveness; QALY Expected to Be Main Index
July 24, 2015
REGULATORY
- Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
- Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
- MHLW Clarifies Use of Real-World Data in Drug Applications
March 5, 2026
- MHLW Expands Eligibility for “Specific-Use Drug” Designation
March 5, 2026
- MHLW to Launch Priority Review Pathway for Overseas Alternatives amid Drug Shortages
March 5, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…